Akouos, Inc. AKUS
Set alert
13.29 0.00 0.00%
At close · Nov 30
13.16 Day range 13.33
52-week range unavailable
- Open
- 13.20
- Prev close
- 13.29
- Mkt cap
- 491.02M
- Vol
- 1.79M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 13.16
- High
- 13.33
- Forward P/E
- -6.78
- Beta
- -0.56
- Short ratio
- 0.66
- Inst. own
- 104.91%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 14, 2022
- 50-d avg
- 11.93
- 200-d avg
- 5.81
- 1y target
- 8.50
2Y chart
Events in this range
- Nov 12, 2021Earnings: —; estimate -0.63; surprise —%
- Mar 29, 2022Earnings: —; estimate -0.66; surprise —%
- May 12, 2022Earnings: —; estimate -0.73; surprise —%
- May 18, 2022Rating: Piper Sandler · — → Overweight
- Aug 15, 2022Earnings: —; estimate -0.76; surprise —%
- Sep 29, 2022Rating: William Blair · — → Outperform
- Oct 18, 2022Downgrade: HC Wainwright & Co. · Buy → Neutral
- Oct 19, 2022Downgrade: William Blair · Outperform → Market Perform
- Oct 19, 2022Downgrade: Piper Sandler · Overweight → Neutral
- Nov 14, 2022Earnings: —; estimate -0.64; surprise —%
Signals (46)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Nov 30, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 2, 2022 | 3 years ago |
| RSI: Overbought | Oct 18, 2022 | 4 years ago |
| RSI: Overbought | Sep 29, 2022 | 4 years ago |
| SMA: Bullish | Sep 27, 2022 | 4 years ago |
| SMA: Bearish | Sep 22, 2022 | 4 years ago |
| SMA: Bullish | Sep 16, 2022 | 4 years ago |
| RSI: Overbought | Sep 16, 2022 | 4 years ago |
| SMA: Bullish | Sep 12, 2022 | 4 years ago |
| MACD: Buy Signal | Sep 12, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 7, 2022 | 4 years ago |
| SMA: Bearish | Sep 6, 2022 | 4 years ago |
| SMA: Bullish | Sep 2, 2022 | 4 years ago |
| SMA: Bearish | Aug 25, 2022 | 4 years ago |
| SMA: Bullish | Aug 24, 2022 | 4 years ago |
| SMA: Bearish | Aug 19, 2022 | 4 years ago |
| SMA: Bullish | Aug 18, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 15, 2022 | 4 years ago |
| SMA: Bearish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Jul 8, 2022 | 4 years ago |
| SMA: Bearish | Jul 6, 2022 | 4 years ago |
| SMA: Bullish | Jul 5, 2022 | 4 years ago |
| SMA: Bearish | Jul 1, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 1, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 23, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 21, 2022 | 4 years ago |
| SMA: Bullish | Jun 17, 2022 | 4 years ago |
| SMA: Bearish | Jun 16, 2022 | 4 years ago |
| RSI: Overbought | Jun 8, 2022 | 4 years ago |
| SMA: Bullish | Jun 7, 2022 | 4 years ago |
| MACD: Buy Signal | May 27, 2022 | 4 years ago |
| MACD: Sell Signal | May 25, 2022 | 4 years ago |
| RSI: Oversold | May 6, 2022 | 4 years ago |
| MACD: Buy Signal | May 5, 2022 | 4 years ago |
| RSI: Oversold | Apr 21, 2022 | 4 years ago |
| RSI: Oversold | Apr 18, 2022 | 4 years ago |
| RSI: Oversold | Apr 12, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 8, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 18, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 15, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 8, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 4, 2022 | 4 years ago |
| RSI: Oversold | Mar 4, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 9, 2022 | 4 years ago |
| RSI: Oversold | Jan 19, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 11, 2022 | 4 years ago |
Key statistics
- Market cap
- 491.02M
- Enterprise value
- 351.88M
- Trailing P/E
- 0.00
- Forward P/E
- -6.78
- PEG ratio
- -0.15
- Price / sales
- 0.00
- Price / book
- 2.71
- EPS (TTM)
- -2.83
- Beta
- -0.56
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -59.79M
- Total cash
- 169.33M
- Total debt
- 35.37M
- Return on equity
- -42.37%
- Shares outstanding
- 36.95M
- Short % of float
- 3.63%
- 50-day average
- 11.93
- 200-day average
- 5.81
Analyst view
Consensus: hold
Hold
Price target (mean) 8.50 -36.0% downside
Now 13.29
- Target (low)
- 4.00
- Target (mean)
- 8.50
- Target (high)
- 13.00
Next earnings
Nov 14, 2022
Expected Nov 14, 2022. Consensus EPS estimate -0.75.
Financials — quick view
AKUS Revenue — quarterly 0
AKUS Net income — quarterly -19.84M
AKUS EPS — quarterly -0.54
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2022 | Sep 1, 2022 | -0.64 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | -0.76 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.73 | — | — | — |
| Mar 29, 2022 | Dec 1, 2021 | -0.66 | — | — | — |
| Nov 12, 2021 | Sep 1, 2021 | -0.63 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -0.48 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2022 | Piper Sandler | down | Overweight | Neutral |
| Oct 19, 2022 | William Blair | down | Outperform | Market Perform |
| Oct 18, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Sep 29, 2022 | William Blair | init | — | Outperform |
| May 18, 2022 | Piper Sandler | main | — | Overweight |
| Apr 27, 2021 | HC Wainwright & Co. | init | — | Buy |
About Akouos, Inc.
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- akouos.com
News
- Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
- Lilly and Akouos Announce Expiration of Akouos Tender Offer
- SHAREHOLDER ALERT: Weiss Law Investigates Akouos, Inc.
- Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022
- AKOUOS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akouos, Inc. - AKUS
- Why Is Akouos (AKUS) Stock Up 85% Today?
- Why Akouos Stock Is on Fire Today
- Eli Lilly to buy genetic medicine developer Akouos for $487 million
- Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss
- Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
Your note
Sign in to keep a note on AKUS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 5AM VENTURES V, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 28, 2020 | 0 |
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2020 | 0 |
| BEHBAHANI ALI | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2020 | 0 |
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2020 | 0 |
| FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2020 | 0 |
| KEARNY ACQUISITION CORP | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 29, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.41% | 4,582,532 | 60.90M | Sep 29, 2022 |
| NEA Management Company, LLC | 11.64% | 4,298,488 | 57.13M | Sep 29, 2022 |
| 5AM Venture Management, LLC | 11.20% | 4,135,784 | 54.96M | Sep 29, 2022 |
| Federated Hermes, Inc. | 10.80% | 3,988,967 | 53.01M | Sep 29, 2022 |
| VR Adviser, LLC | 7.58% | 2,800,566 | 37.22M | Sep 29, 2022 |
| EcoR1 Capital, LLC | 5.35% | 1,975,984 | 26.26M | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Small Cap Fund | 5.28% | 1,950,000 | 25.92M | Jul 30, 2022 |
| Federated Hermes Kaufmann Fund | 3.74% | 1,380,000 | 18.34M | Jul 30, 2022 |
| Fidelity Select Portfolios - Biotechnology | 2.99% | 1,103,186 | 14.66M | Aug 30, 2022 |
| Fidelity Growth Company Fund | 2.46% | 908,209 | 12.07M | Aug 30, 2022 |
| Vanguard Total Stock Market Index Fund | 1.46% | 538,627 | 7.16M | Jun 29, 2022 |
| BlackRock Health Sciences Trust II | 0.78% | 287,850 | 3.83M | Jun 29, 2022 |